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Abstract
IMPORTANCE Previous comparisons of surgery and stereotactic body radiotherapy (SBRT) for
early-stage (ES) non–small cell lung cancer (NSCLC) did not account for the extent of regional lymph
node examination (LNE) during surgery.
OBJECTIVE To compare long-term overall survival (OS) of patients with ES NSCLC after surgery vs
SBRT when the extent of regional LNE in patients undergoing surgery is thoroughly considered.
DESIGN, SETTING, AND PARTICIPANTS Cohort study with survival comparisons using the
multivariable Cox proportional hazards model and after propensity score matching. Data from the
National Cancer Database were analyzed fromOctober 28, 2018, through April 18, 2019. Patients
with ES NSCLC diagnosed between January 1, 2004, and December 31, 2015, who underwent any
curative-intent surgery or SBRT were included.
MAINOUTCOMESANDMEASURES Long-termOS.
RESULTS Of 104 709 total patients, 91 330 underwent surgery (42 508 [46.5%]male; median
[interquartile range] age, 68 [61-75] years) and 13 379 received SBRT (6065 [45.3%]male; median
[interquartile range] age, 75 [68-81] years). Surgery, especially lobectomy (hazard ratio [HR], 0.53;
95% CI, 0.50-0.56), and regional LNE, especially when more than 10 lymph nodes were examined
(HR, 0.73; 95% CI, 0.69-0.77), were associated with better long-term OS (P < .001).
Pneumonectomywas not associated with reducedmortality risk when 0 nodes were examined (HR
for stage T1, 1.43; 95% CI, 0.67-3.06; P = .35; HR for stage T2-T3, 0.62; 95% CI, 0.34-1.13; P = .12) or
whenmore than 15 nodes were examined for stage T1 disease in patients younger than 80 years (HR,
0.77; 95% CI, 0.54-1.09; P = .14) or when patients aged 80 years or older received regional LNE of
any extent (>15 nodes examined: HR for stage T1, 0.65; 95%CI, 0.16-2.64; P = .54; HR for stage T2-T3,
0.90; 95%CI, 0.50-1.60; P = .71). Less extensive surgerywas not associatedwith improvedOSwhen
0 nodes were examined in patients aged 80 years or older with stage T2 to T3 tumors (HR for
lobectomy, 0.90; 95% CI, 0.65-1.25; P = .53) and in selected operable patients older than 75 years
with stage T1 tumors (HR for lobectomy, 1.07; 95% CI, 0.57-2.00; P = .84).
CONCLUSIONS ANDRELEVANCE This study found that, overall, surgery coupled with regional LNE
of appropriate extent was associated with the best long-termOS in patients with ES NSCLC.
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Key Points
Question How does the long-term
survival after curative-intent surgery
with regional lymph node examination
of various extents compare with long-
term survival after stereotactic body
radiotherapy for early-stage non–small
cell lung cancer?
Findings In this cohort study of
104 709 patients in the US National
Cancer Database with early-stage
non–small cell lung cancer, those who
received surgery coupled with regional
lymph node examination of an
appropriate extent had significantly
better long-term survival than those
who received stereotactic body
radiotherapy.
Meaning These findings suggest that
curative-intent surgery, when coupled
with regional lymph node examination,
is generally associated with the best
long-term overall survival in patients
with early-stage non–small cell
lung cancer.
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Introduction
Lung cancer is the leading cause of cancer-related death in the United States and worldwide, with
non–small cell lung cancer (NSCLC) accounting for more than 80% of all cases diagnosed.1-3 The
standard curative treatment for early-stage (ES) NSCLC (stage I or II) is lobectomy combined with
systematic or lobe-specific lymph node dissection and/or sampling, although other options of
anatomic pulmonary resection and noninvasive treatments are also available.3-7 Owing to the
prognostic and therapeutic implications of regional nodal metastasis, accurate lymph node staging
based on the standard of care is of critical importance during surgery for ES NSCLC.7-9 However, the
number of regional lymph nodes examined during lung cancer surgery is highly variable in daily
clinical practice. Many patients who underwent lobar or greater resection had no lymph node
examination (LNE), fewer than 6 lymph nodes examined, or inadequate retrieval of intrapulmonary
lymph nodes from resection specimens.9-14 All led to understaging and worse-than-expected stage-
stratified survival, while themost optimal number of regional lymph nodes to be examinedmay be
well beyond what was recommended.11,14
Heterogeneity in stage-stratified survival in pathologically N0 NSCLC due to variations in the
extent of regional LNE imposes a challenge in the comparison of surgery with other noninvasive
therapies, such as stereotactic body radiotherapy (SBRT), for ES NSCLC. In SBRT, an ablative dose of
radiation is delivered to the primary tumor over several daily fractions. It has been associated with
excellent local control in ES NSCLC.15,16 However, how it compares with surgery in patients with ES
NSCLC remains controversial, with conflicting results being reported.17-27 One reasonmay be that the
extent of regional LNE during surgery has not been fully accounted for in previous comparisons. In
this study, we compare the long-term overall survival (OS) following curative-intent surgery with OS
following SBRT for ES NSCLC, with the extent of regional LNE in patients undergoing surgery
thoroughly considered.
Methods
Data Source
We used data from the National Cancer Database for patients with lung cancer diagnosed between
2004 and 2015. This was the most recent data set available at the time of the study. The National
Cancer Database is a joint project of the Commission on Cancer of the American College of Surgeons
and the American Cancer Society. This hospital-based, nationwide database captures approximately
70% of incident cancer cases in the United States. It provides deidentified data subsets to
investigators from Commission on Cancer–accredited programs through an online application
process. The studywas exempt from review by the institutional review board of theMarshfield Clinic.
Informed consent was waived as there was no increased harm to patients owing to the study’s
retrospective nature. This study followed the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) reporting guideline.
Study Cohort
First, patients with primary NSCLC and no prior diagnosis of anymalignant neoplasmwere selected
from the requested data set. This study cohort was limited to patients with histological diagnosis of
invasive cancer who underwent treatment in a Commission on Cancer facility. Next, patients with
clinical stage of T1 to T3, N0, andM0, as defined by the American Joint Committee on Cancer AJCC
Staging Manual, 8th Edition staging criteria, were selected based on clinical TNM staging information
and tumor size. From this study population, we created a surgery cohort and a SBRT cohort.
For the surgery cohort, only patients who underwent wedge resection, segmentectomy,
lobectomy, or pneumonectomywere included. Neoadjuvant or adjuvant systemic therapy
(chemotherapy or immunotherapy) or adjuvant radiotherapywas allowed. Patients withmissing data
on surgery starting time and the starting time for other treatments were excluded. For the SBRT
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cohort, patients who received primary photon or proton beam irradiation over 1 to 10 fractions to the
thorax were selected. Patients with missing information regarding treatment start or end days from
diagnosis were excluded. Patients who received additional treatments other than chemotherapy or
immunotherapy or with unknown information on treatments other than radiotherapy were
excluded. Only patients who were treated with dose fraction schedules per National Comprehensive
Cancer Network guidelines that are equivalent to a biologically effective dose of at least 100 Gy10
(Gy calculated with an α to β ratio of 10 Gy) were included. Biologically effective dose was calculated
as total dose × [1 + fractional dose / (α / β)]. These included 27 to 34 Gy in 1 fraction, 45 to 60 Gy in
3 fractions, 48 to 50 Gy in 4 fractions, 50 to 55 Gy in 5 fractions, 60 Gy in 8 fractions, and 70 Gy in 10
fractions (Figure 1).
StudyVariables
Patient, tumor, and treatment characteristics were provided by the National Cancer Database or
derived from the variables provided. They include year of diagnosis, age, sex, race, Charlson
Comorbidity Index score, anatomical tumor location, tumor histology, tumor size, clinical T stage,
regional LNE (the total number of regional lymph nodes removed and examined) in patients who
underwent surgery, tumor extension, nodule plurality in the ipsilateral lung, systemic therapy,
insurance, urban vs rural status, income quartile, education quartile, and facility type, location,
and volume.
Figure 1. FlowDiagram for Patient Selection
1 393 073 Patients with lung cancer diagnosed
between 2004 and 2015
933 132 Primary NSCLC with histology
confirmation and treated in a CoC facility
172 208 Clinical T1-T3, N0, M0, NSCLC
459 941 Excluded (not first primary diagnosis, no
diagnostic confirmation, primary site other
than lung, noninvasive histology, histology
other than NSCLC, and treatment at a
non-CoC facility)
760 924 Excluded (clinical stage other than T1-T3,
N0, M0)
15 810 Excluded (radiotherapy or surgery not
primary treatment)
47 359 Radiotherapy as primary
treatment
109 039 Surgery as primary
treatment
33 980 Excluded (SBRT not primary
treatment, missing
radiotherapy start date,
additional treatments other
than chemotherapy or 
immunotherapy)
17 709 Excluded (missing surgery
start date, additional
treatments other than
chemotherapy, 
immunotherapy,
or adjuvant radiotherapy)
13 379 SBRT cohort
89 27-34 Gy in 1 fraction
4262 45-60 Gy in 3 fractions
3690 48-50 Gy in 4 fractions
5104 50-55 Gy in 5 fractions
165 60 Gy in 8 fractions
69 70 Gy in 10 fractions
91 330 Surgery cohort
13 377 Wedge resection
3146 Segmentectomy
72 448 Lobectomy
2359 Pneumonectomy
Clinical stage T1 to T3, N0, M0 non–small cell lung
cancer (NSCLC) was determined according to the
criteria of the American Joint Committee on Cancer
AJCC Staging Manual, 8th Edition. CoC indicates
Commission on Cancer; SBRT, stereotactic body
radiotherapy.
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Outcome
The primary end point was OS, which wasmeasured from the time of diagnosis to date of death from
any cause or last follow-up. Patients still alive or without any clear indication of death at last follow
upwere censored at that point.
Statistical Analysis
The data were analyzed from October 28, 2018, through April 18, 2019. Descriptive statistics were
used to summarize patients’ baseline and clinical characteristics. Categorical data were described
using contingency tables including counts and percentages. Continuously scaledmeasures were
summarized with descriptive statistical measures (ie, mean [standard deviation] or median [range]).
Independence between categorical variables was assessed with the χ2 test. Differences between
the 2 groups in continuous variables were assessed with theWilcoxon rank sum test.
Overall survival was estimated using the Kaplan-Meier method, and compared between the
SBRT and surgery cohorts using the log-rank test in a univariate analysis. In themultivariate analysis,
the Cox proportional hazards regression model stratified by tumor grade was used to compare
survival following different treatments while adjusting for all major known variables (listed in the
Study Variables subsection ofMethods). The proportional hazards assumptionwas assessedwith the
Grambsch-Therneau test.28 The stratified Cox model was fitted if a variable associated with OS did
not satisfy the proportional hazards assumption.
Next, stratified multivariable Coxmodels were used to compare surgery and SBRT in more
homogeneous populations stratified by independent variables, such as age, T stage, and the extent
of regional LNE (patients who underwent surgery only). In particular, a grade-stratified multivariable
Coxmodel that adjusted for potential confounderswas used to compare treatments in each stratum.
Propensity score matching was also performed to compare surgery and SBRT incorporating
preoperative risk factors significantly associated with OS. Sublobar resection (wedge resection or
segmentectomy) and lobar resection (lobectomy or pneumonectomy) were compared with SBRT
separately after propensity score matching. Propensity scores were calculated using logistic
regression with treatment as the dependent variable. Patients were matched 1:1 using our
preliminary propensity score model in which the estimand is themean treatment effect on SBRT.29
Success of propensity score matching was assessed bymeasuring the balance of the confounders for
every matching variable.
All statistical tests were 2-sided and P < .05 was considered statistically significant. Statistical
analyses were carried out using SAS statistical software version 9.1 (SAS Institute) and R statistical
software version 3.0.3 (R Project for Statistical Computing) package “Matching.”29
Results
Study Cohort Characteristics
Of 104 709 total patients, 91 330 (42 508 [46.5%]male; median [interquartile range] age, 68 [61-75]
years) were included in the surgery cohort, and 13 379 (6065 [45.3%]male; median [interquartile
range] age, 75 [68-81] years) were included in the SBRT cohort. Most patients who underwent
surgery received either lobectomy (79.3%) or wedge resection (14.7%). Major baseline patient
characteristics are listed in Table 1. Receiving SBRTwas associated with older age, lower clinical T
stage, adenocarcinoma histology, tumor confinement to 1 lung, and single tumor nodule.
Examination of 1 to 10, 11 to 15, andmore than 15 regional lymph nodes was conducted in 55.8%,
15.6%, and 14.2% of patients, respectively, in the surgery cohort. Most patients did not receive any
systemic therapy as part of their primary treatment (eTable 1 in the Supplement). Regional LNE of
limited extent and regional LN aspiration or biopsy were performed in 4.21% and 3.92% of the
patients in the SBRT cohort, respectively. In the SBRT cohort, regional LNE of limited extent (HR vs
SBRT alone, 1.10; 95% CI, 0.96-1.28; P = .17) or regional LN aspiration or biopsy (HR vs SBRT alone,
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Table 1. Patient Characteristics
Characteristic
No. (%)
P ValueSBRT (n = 13 379) Surgery (n = 91 330)
Age, median (IQR), y 75 (68-81) 68 (61-75) <.001
Year of diagnosis
2004-2009 1974 (14.8) 26 730 (29.3)
<.001
2010-2015 11 405 (85.2) 64 600 (70.7)
Sex
Male 6065 (45.3) 42 508 (46.5)
.009
Female 7314 (54.7) 48 822 (53.5)
Race
White 11 887 (88.9) 80 521 (88.2)
<.001Black 1180 (8.8) 7423 (8.1)
Other 215 (1.6) 2789 (3.1)
Charlson Comorbidity Index score
0 6990 (52.3) 44 097 (48.3)
<.0011 3818 (28.5) 32 968 (36.1)
2 or 3 2571 (19.2) 14 265 (15.6)
Grade
Well differentiated 1078 (8.1) 14 249 (15.6)
<.001
Moderately differentiated 2448 (18.3) 41 726 (45.7)
Poorly differentiated or undifferentiated 2826 (21.1) 30 501 (33.4)
Unknown 7027 (52.5) 4854 (5.3)
Histology
Adenocarcinoma 6522 (48.8) 58 070 (63.6)
<.001Squamous cell carcinoma 5143 (38.4) 27 359 (30.0)
Other 1714 (12.8) 5901 (6.5)
Anatomical site
Right upper lobe 4448 (33.3) 31 631 (34.6)
<.001
Right middle lobe 589 (4.4) 4442 (4.9)
Right lower lobe 2339 (17.5) 16 302 (17.9)
Left upper lobe 3768 (28.2) 23 542 (25.8)
Left lower lobe 1940 (14.5) 12 779 (14.0)
Overlapping 30 (0.2) 938 (1.0)
Lung, not otherwise specified 214 (1.6) 1247 (1.4)
Other 51 (0.4) 449 (0.5)
Clinical T stage
T1a 487 (3.6) 5759 (6.3)
<.001
T1b 4706 (35.2) 28 647 (31.4)
T1c 4149 (31.0) 20 178 (22.1)
T2a 2456 (18.4) 19 969 (21.9)
T2b 794 (5.9) 6907 (7.6)
T3 664 (5.0) 9706 (10.6)
Other 123 (0.9) 164 (0.2)
Tumor extension
Confined to 1 lung 9257 (69.2) 49 026 (53.7)
<.001
Adjacent lobe extension 20 (0.2) 205 (0.2)
Central location 121 (0.9) 2693 (3.0)
Pleura, chest wall, or diaphragm 289 (2.2) 14 061 (15.4)
Atelectasis or obstructive pneumonia 149 (1.1) 929 (1.0)
Unknown 3543 (26.5) 24 416 (26.7)
(continued)
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0.99; 95% CI, 0.97-1.02; P = .69) were not associated with any significant difference in OS when
compared with SBRT alone.
Survival Analysis
Patient survival stratified by treatment approach is shown in Figure 2A. The unadjusted 5-year OS
was 48.1% to 64.6% in the surgery cohort depending on the type of surgery performed and 30.4% in
the SBRT cohort (HR for wedge resection vs SBRT, 0.55; 95% CI, 0.52-0.57; P < .001; HR for
segmentectomy vs SBRT, 0.48; 95% CI, 0.43-0.49; P < .001; HR for lobectomy vs SBRT, 0.40; 95%
CI, 0.39-0.42; P < .001; HR for pneumonectomy vs SBRT, 0.71; 95% CI, 0.67-0.76; P < .001). The
improved long-termOS associated with surgery compared with SBRTwas augmented by the
conduct of regional lymph node surgery and increased number of regional lymph nodes examined
(Figure 2B and C). In patients who underwent surgery at the primary tumor site, the conduct of
regional lymph node surgery was associated with better 5-year OS (63.6% vs 49.8%; HR vs no lymph
node surgery, 0.66; 95% CI, 0.64-0.69; P < .001). For patients who underwent surgery with 0, 1 to
10, 11 to 15, and more than 15 lymph nodes examined, 5-year OS was 50.2%, 62.9%, 65.3%, and
64.6%, respectively (HR for 1-10 lymph nodes examined vs 0, 0.68; 95% CI, 0.66-0.71; P < .001; HR
for 11-15 lymph nodes examined vs 0, 0.62; 95% CI, 0.59-0.64; P < .001; HR for >15 lymph nodes
examined vs 0, 0.64; 95% CI, 0.61-0.68; P < .001).
Primary treatment and the number of regional lymph nodes examined along with all baseline
characteristics, except chemotherapy and immunotherapy as part of the primary treatment, were
significantly associated with survival in a univariate analysis (eTable 2 in the Supplement). After
stratifying for tumor grade and adjusting for all variables that may affect the entire patient
population’s prognosis in a multivariate Coxmodel (Table 2), surgical treatments were found to be
associated with a reduction in mortality risk over SBRT (wedge resection: HR, 0.67; 95% CI,
0.64-0.71; P < .001; segmentectomy: HR, 0.60; 95% CI, 0.56-0.65; P < .001; lobectomy: HR, 0.53;
95% CI, 0.50-0.56; P < .001; pneumonectomy: HR, 0.75; 95% CI, 0.69-0.82; P < .001). For the
extent of regional LNE as an independent variable, examination of more than 10 lymph nodes was
associated with the greatest reduction in mortality risk when compared with no LNE (11-15 lymph
nodes examined: HR, 0.73; 95% CI, 0.69-0.77; P < .001; >15 lymph nodes examined: HR, 0.73; 95%
CI, 0.69-0.77; P < .001) in the entire patient population. In the Cox model, other variables that were
associated with a reduction in mortality risk were younger age, lower Charlson Comorbidity Index
Table 1. Patient Characteristics (continued)
Characteristic
No. (%)
P ValueSBRT (n = 13 379) Surgery (n = 91 330)
Separate nodules in the ipsilateral lung
None 10 854 (81.1) 61 160 (67.0)
<.001
Same lobe 297 (2.2) 2622 (2.9)
Different lobes 0 0
Unknown 2228 (16.7) 27 548 (30.2)
Scope of lymph node surgery
No 12 750 (95.3) 7437 (8.1)
<.001Yes 599 (4.5) 83 573 (91.5)
Unknown 30 (0.2) 320 (0.4)
Regional lymph nodes examined, No.
0 12 238 (91.5) 7382 (8.1)
<.001
1-10 371 (2.8) 50 977 (55.8)
11-15 17 (0.1) 14 256 (15.6)
>15 14 (0.1) 12 944 (14.2)
Other 739 (5.5) 5771 (6.3)
Abbreviations: IQR, interquartile range; SBRT,
stereotactic body radiotherapy.
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score, adenocarcinoma histology, nonoverlapping location, tumor limited to the lung parenchyma,
and solitary tumor nodule.
Survival Comparisons in Stratified Analyses Using theMultivariable CoxModel
Survival after surgery was also compared with survival after SBRT in 16 patient population partitions
that were stratified by age, clinical T stage, and then the extent of regional LNE in surgery patients.
A stratified multivariable Cox model was used to compare OS after surgery with OS after SBRT
adjusting for all potential confounding variables. Overall, surgery was associated with a reduction in
mortality risk over SBRT. Reduction in mortality risk became more obvious as more regional lymph
nodes were examined (eFigure in the Supplement). In patients younger than 80 years, sublobar
resections and lobectomywith regional LNE of any extent were associated with a reduction in
mortality risk over SBRT (>15 nodes examined: HR for stage T1, 0.65; 95% CI, 0.16-2.64; P = .54; HR
for stage T2-T3, 0.90; 95% CI, 0.50-1.60; P = .71) (Table 3). Pneumonectomy was not associated
with any reduction inmortality risk over SBRTwhen it was coupledwith no regional LNE (for stage T1:
HR, 1.43; 95% CI, 0.67-3.06; P = .35; for stage T2-T3: HR, 0.62; 95% CI, 0.34-1.13; P = .12) or LNE of
Figure 2. Overall Survival for Stereotactic Body Radiotherapy (SBRT) vs Surgery
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Table 2. Mortality Risk Based on Independent Variables AssociatedWith Survival
Study Variables
Univariate Analysis
P Value HR (95% CI)a P Value
Age, y
≤65
<.001
1 [Reference]
66-70 1.18 (1.14-1.22) <.001
71-75 1.38 (1.33-1.43) <.001
76-80 1.68 (1.62-1.75) <.001
>80 1.90 (1.82-1.98) <.001
Charlson Comorbidity
Index score
0
<.001
1 [Reference]
1 1.18 (1.15-1.21) <.001
2 or 3 1.48 (1.44-1.53) <.001
Histology
Adenocarcinoma
<.001
1 [Reference]
Squamous cell carcinoma 1.12 (1.09-1.14) <.001
Adenosquamous 1.38 (1.30-1.47) <.001
Large cell carcinoma 1.20 (1.10-1.31) <.001
Other (lymphoepithelioma,
undifferentiated non–small
cell lung cancer)
1.15 (1.09-1.21) <.001
Tumor location
Right upper lobe
<.001
1 [Reference]
Right middle lobe 1.07 (1.01-1.13) .02
Right lower lobe 1.11 (1.08-1.15) <.001
Left upper lobe 1.01 (0.98-1.04) .39
Left lower lobe 1.02 (0.98-1.06) .30
Overlapping 1.23 (1.11-1.37) <.001
Lung, not otherwise specified 1.17 (1.07-1.28) .001
Other 1.00 (0.86-1.17) .96
T stage
T1
<.001
1 [Reference]
T2 1.13 (1.09-1.19) <.001
T3 1.36 (1.26-1.47) <.001
Tumor extension
Confined to 1 lung
<.001
1 [Reference]
Adjacent lobe extension 1.50 (1.16-1.93) .002
Mainstem bronchus,
carina, or hilum
1.05 (0.98-1.12) .17
Other central structures 1.52 (1.32-1.73) <.001
Pleura, chest wall,
or diaphragm
1.35 (1.30-1.40) <.001
Atelectasis or obstructive pneumonia 1.13 (1.02-1.25) .02
Separate nodules,
ipsilateral lung
None
<.001
1 [Reference]
Yes
Same lobe 1.13 (1.04-1.22) .004
Different lobe involved 1.32 (1.14-1.53) <.001
Separate tumor nodules,
not otherwise specified
1.52 (1.02-2.25) .04
Not available or unknown 1.26 (1.07-1.49) .005
(continued)
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more than 15 lymph nodes if patients had stage T1 tumors (HR, 0.77; 95% CI, 0.54-1.09; P = .14). In
patients aged 80 years or older, pneumonectomywith regional LNE of any extent was not associated
with any reduction inmortality risk over SBRT (Table 3). Sublobar resection (mainly wedge resection)
and lobectomywere generally associated with a reduction in mortality risk over SBRT, except in
patients with stage T2 to T3 tumors who did not undergo any regional LNE (wedge resection: HR,
0.81; 95% CI, 0.64-1.02; P = .07; segmentectomy: HR, 1.15; 95% CI, 0.65-2.05; P = .64; lobectomy:
HR, 0.90; 95% CI, 0.65-1.25; P = .53).
Treatments were further compared in patients older than 75 years with Charlson Comorbidity
Index score of 0 and stage T1 tumors after adjusting for other variables, including the extent of
regional LNE in patients who underwent surgery (eTable 3 in the Supplement). Only patients in the
SBRT cohort who were operable but refused surgery and received a dose at least biologically
equivalent to 50 Gy delivered in 4 fractions were included. In this subpopulation, sublobar resection
(HR, 1.17; 95%CI, 0.64-2.15; P = .60) and lobectomy (HR, 1.07; 95%CI, 0.57-2.00; P = .84)were not
associated with any reduction in mortality risk, while pneumonectomy was associated with an
increase in mortality risk over SBRT (HR, 3.20; 95% CI, 1.20-8.49; P = .02).
Survival Comparison in Propensity Score–Matched Cohorts
For the propensity score–matched cohorts, the balance for each variable indicates good balance
between 12 632 patients undergoing sublobar resection and 12 632 patients undergoing SBRT, as well
as 12 632 patients undergoing lobar resection and 12 632 patients undergoing SBRT (eTable 4 and
eTable 5 in the Supplement). Both sublobar resection (HR, 0.56; 95% CI, 0.54-0.58, P < .001) and
lobar resection (HR, 0.47; 95% CI, 0.45-0.49, P < .001) were associated with a reduction in mortality
risk compared with SBRT.
Discussion
Overall, all surgical modalities studied were associated with superior long-termOSwhen compared
with SBRT in patients with clinical stage T1 to T3, N0, M0NSCLC (Figure 2A). This survival advantage
is further enhanced by regional LNE, especially whenmore than 10 lymph nodes were examined
(Figure 2B and C). Although surgery’s superiority over SBRT has been corroborated in many
studies,17-23 the influence of regional lymph node assessment on such comparisons has not, to our
knowledge, been fully analyzed previously. Regional LNE is an important factor to consider when
comparing surgery and SBRT for ES NSCLC owing to its association with stage-stratified survival after
surgery for NSCLC.9-14 In the current study, the survival advantage associatedwith surgery over SBRT
remained after adjusting for the number of regional lymph nodes examined and other known
Table 2. Mortality Risk Based on Independent Variables AssociatedWith Survival (continued)
Study Variables
Univariate Analysis
P Value HR (95% CI)a P Value
Regional lymph nodes examined, No.
0
<.001
1 [Reference]
1-10 0.82 (0.78-0.85) <.001
11-15 0.73 (0.69-0.77) <.001
>15 0.73 (0.69-0.77) <.001
Treatment
Stereotactic body radiotherapy
<.001
1 [Reference]
Wedge resection 0.67 (0.64-0.71) <.001
Segmentectomy 0.60 (0.56-0.65) <.001
Lobectomy 0.53 (0.50-0.56) <.001
Pneumonectomy 0.75 (0.69-0.82) <.001
Abbreviation: HR, hazard ratio.
a Also adjusted for sex, race, tumor size, systemic
therapy, insurance, urban/rural, income quartile,
education quartile, facility type, facility location, and
facility volume quartile.
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Table 3. Age- and T Stage–DependentMortality Risk AssociatedWith Surgery vs SBRT
in 16 Patient-Population Partitions
Treatment
Age, y
<80 ≥80
HR (95% CI)a P Value HR (95% CI)a P Value
Stage T1
LNE: 0
No. 10 986 3638
SBRT 1 [Reference] 1 [Reference]
Wedge resection 0.62 (0.57-0.67) <.001 0.83 (0.73-0.95) .006
Segmentectomy 0.51 (0.41-0.63) <.001 0.73 (0.51-1.05) .09
Lobectomy 0.47 (0.41-0.54) <.001 0.68 (0.51-0.91) .008
Pneumonectomy 1.43 (0.67-3.06) .35
LNE: 1-10
No. 35 109 5459
SBRT 1 [Reference] 1 [Reference]
Wedge resection 0.47 (0.44-0.51) <.001 0.62 (0.54-0.72) <.001
Segmentectomy 0.39 (0.35-0.45) <.001 0.68 (0.54-0.87) .002
Lobectomy 0.35 (0.33-0.38) <.001 0.52 (0.47-0.58) <.001
Pneumonectomy 0.63 (0.49-0.81) <.001 1.75 (0.65-4.71) .27
LNE: 11-15
No. 13 477 3304
SBRT 1 [Reference] 1 [Reference]
Wedge resection 0.41 (0.33-0.51) <.001 0.38 (0.21-0.66) <.001
Segmentectomy 0.40 (0.28-0.57) <.001 0.26 (0.06-1.03) .06
Lobectomy 0.32 (0.30-0.35) <.001 0.47 (0.39-0.56) <.001
Pneumonectomy 0.66 (0.45-0.94) .02 1.03 (0.25-4.30) .97
LNE: >15
No. 12 032 3248
SBRT 1 [Reference] 1 [Reference]
Wedge resection 0.34 (0.26-0.46) <.001 0.31 (0.13-0.75) .01
Segmentectomy 0.29 (0.18-0.46) <.001 0.86 (0.42-1.75) .67
Lobectomy 0.33 (0.30-0.37) <.001 0.46 (0.38-0.55) <.001
Pneumonectomy 0.77 (0.54-1.09) .14 0.65 (0.16-2.64) .54
Stage T2-T3
LNE: 0
No. 3770 1628
SBRT 1 [Reference] 1 [Reference]
Wedge resection 0.62 (0.54-0.71) <.001 0.81 (0.64-1.02) .07
Segmentectomy 0.66 (0.49-0.88) .005 1.15 (0.65-2.05) .64
Lobectomy 0.41 (0.35-0.49) <.001 0.90 (0.65-1.25) .53
Pneumonectomy 0.62 (0.34-1.13) .12 3.07 (0.66-14.15) .15
LNE: 1-10
No. 19 584 3465
SBRT 1 [Reference] 1 [Reference]
Wedge resection 0.52 (0.47-0.59) <.001 0.63 (0.51-0.78) <.001
Segmentectomy 0.51 (0.43-0.59) <.001 0.49 (0.35-0.68) <.001
Lobectomy 0.39 (0.36-0.42) <.001 0.57 (0.50-0.65) <.001
Pneumonectomy 0.50 (0.43-0.58) <.001 0.90 (0.57-1.42) .65
(continued)
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variables in a multivariable Coxmodel (Table 2). Among all surgical modalities, lobectomywas
associated with the lowest mortality risk. Regional LNEwas independently associated with survival,
and examination of more than 10 lymph nodes was associated with the lowest mortality risk.
Surgery’s association with a reduction in mortality risk over SBRT, especially when coupled with
regional LNE, was also demonstrated in a comparison after propensity score matching (eTable 4 and
eTable 5 in the Supplement). Overall, our findings are consistent with previous studies and the
currently guidelines, which support lobectomywith adequate regional lymph node assessment to be
the standard of care in operable patients with ES NSCLC.3-5,17-23
At least comparable OS following surgery and SBRT has been suggested in some studies.24-27
However, thorough regional LNE of an adequate number of lymph nodes during surgery might not
have been routinely performed in these studies, leading to underestimation of long-term OS after
surgery. For instance, only 37% to 71.9% of the patients had 6 or more lymph nodes dissected during
surgery in 2 propensity-matched studies that found similar survival following lobectomy and SBRT
for ES NSCLC.24,25 In an analysis of the Surveillance, Epidemiology, and End Results–Medicare
database, similar 3-year OS and lung cancer–specific survival were observed between lobectomy and
SBRT after propensity matching of 502 patients with ES NSCLC.26 In this study, the only known
regional lymph node assessment conducted wasmediastinal lymph node sampling, which was done
in only 8% of the propensity score–matched patients. Althoughmore thorough regional LNE was
required for patients who underwent lobectomy in a pooled study of limited sample size, no details
on the number of nodal stations and lymph nodes examined during surgery were reported.27
How surgery coupled with regional LNE compares with SBRT appeared to be associated with
patient age, T stage, and the extent of surgery for both the primary tumor and regional lymph nodes.
Comparable survival between surgery and SBRTmay be observed in some situations. In further
analysis of more homogeneous population partitions, pneumonectomywas not associated with
lower mortality risk over SBRT regardless of whether regional lymph nodes were examined in
patients aged 80 years and older. In patients younger than 80 years, pneumonectomywas
associated with a significant reduction in mortality risk over SBRT only when coupled with regional
LNE. However, this only occurred when fewer than 16 lymph nodes were examined if patients had T1
tumors. Surgery is known to be associated with a higher incidence of morbidity andmortality
following treatment comparedwith SBRT.27,30 This difference inmortality after treatment appears to
Table 3. Age- and T Stage–DependentMortality Risk AssociatedWith Surgery vs SBRT
in 16 Patient-Population Partitions (continued)
Treatment
Age, y
<80 ≥80
HR (95% CI)a P Value HR (95% CI)a P Value
LNE: 11-15
No. 8206 1909
SBRT 1 [Reference] 1 [Reference]
Wedge resection 0.47 (0.34-0.66) <.001 0.50 (0.22-1.15) .10
Segmentectomy 0.36 (0.22-0.57) <.001 0.46 (0.20-1.05) .06
Lobectomy 0.33 (0.30-0.37) <.001 0.53 (0.44-0.63) <.001
Pneumonectomy 0.47 (0.39-0.56) <.001 1.17 (0.42-3.25) .77
LNE: >15
No. 8333 1971
SBRT 1 [Reference] 1 [Reference]
Wedge resection 0.37 (0.25-0.55) <.001 0.32 (0.12-0.84) .02
Segmentectomy 0.35 (0.20-0.59) <.001 0.61 (0.04-10.50) .73
Lobectomy 0.38 (0.34-0.42) <.001 0.54 (0.45-0.64) <.001
Pneumonectomy 0.49 (0.42-0.58) <.001 0.90 (0.50-1.60) .71
Abbreviations: HR, hazard ratio; LNE, lymph node
examination; SBRT, stereotactic body radiotherapy.
a Adjusted for all potential confounding variables.
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increase with age, while postoperative mortality also increases with more extensive surgery.30 Thus,
very extensive surgery at either the primary site or regional nodal stations may lead to higher-than-
expected risk for postoperative morbidity and mortality. This may be more prominent in older
patients, as they are less likely to tolerate surgery owing to increased likelihood of frailty and
comorbidities. As a result, SBRT may be a reasonable alternative treatment in these situations. For
the same reasons, SBRT appears to be associated with better shorter-term survival over surgery,
especially pneumonectomy (Figure 2).
Surgery was associated with a significant reduction in mortality risk over SBRT in patients with
T2 to T3 tumors whowere aged 80 years and older only when regional lymph nodes were examined.
The risk of regional lymph node involvement increases as T stage increases in NSCLC,31,32 which
makes thorough regional LNEmore critical for ES NSCLC with stage greater than T1. However, it is
unlikely to be the predominant reason in this situation, which was not observed in patients younger
than 80 years. This suggests a strong influence from life expectancy when comparing OS following
surgery and SBRT in patients with ES NSCLC, because older patients are more likely to die of
noncancer causes,18,21 including postoperativemorbidity. Second, patients with T2 to T3 tumors who
underwent surgery but not regional LNEmay have been thought unlikely to benefit from it or unable
to tolerate it, which ismore likely in patients aged 80 years or older. In this situation, SBRTmay be a
good alternative to consider over surgery.
To investigate how surgery compares with SBRT in older patients with longer life expectancy
and a relatively lower risk for regional lymph nodemetastasis based on T stage, further analysis was
conducted in a selected group of operable patients older than 75 years with excellent comorbidity
score and T1 tumors. To ensure adequate radiation dosing, only patients who received a higher-than-
accepted-minimum dose were chosen if they underwent SBRT based on a previous study.27 Our
findings suggest that similar OSmay be observed after surgery and SBRT in operable healthy patients
with small NSCLC tumors. Such similarity was lost when patients with T2a tumors were included in
this subgroup analysis, with superiority associated with lobectomy becoming significant. Our
observationmay be related to a lower risk of regional lymph nodemetastasis in T1 vs T2 to T3 tumors.
However, this remains to be further investigated.
Limitations
This study has limitations. Unlike randomized clinical trials, cohort studies are known to be vulnerable
to selection bias and confounding due to both known and unknown factors.33 As a result, validity of
any conclusion from cohort studies is often questioned with great concern. Many methods exist to
minimize selection bias and confounding, thus increasing the internal validity of a cohort study
comparing different treatments.34,35 In this study, we used the Cox proportional hazards regression
model to account for all available variables that may be of prognostic value to the entire study
population and conducted comparison analyses after propensity score matching. To further
minimize confounding, we also compared treatments in increasingly more homogeneous population
partitions, which is a novel approach that is different frommost population studies comparing
surgery and SBRT. Second, information on regional LNE provided by the National Cancer Database
does not providemore details that may further enhance the quality of the study, such as which nodal
stations were assessed, howmany lymph nodes were taken from each nodal station, and whether
endobronchial ultrasonography-guided mediastinal lymph node staging was done prior to surgery.
These limitations, which can be overcome in randomized clinical trials, make our study more
hypothesis generating than practice defining. However, our study does provide guidance for the
design of future prospective trials and additional evidence for daily clinical decision-making in the
lack of robust results from randomized clinical trials.
Only a small fraction of the patients underwent regional LNE of limited extent, or regional LN
aspiration or biopsy in the SBRT cohort. These lymph node assessment procedures were not
associated with any significant survival benefit in SBRT patients. This finding is also corroborated in
previous studies.36,37 Together with our large sample size of predominantly patients receiving SBRT
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to the primary tumor only, their inclusion in the SBRT cohort most likely will not affect the results of
our analyses or the generalizability of our study, which primarily pertains to patients who received
treatment of the primary tumor only if they received SBRT, with additional regional lymph node
assessment conducted only occasionally.
Conclusions
Curative-intent surgery coupled with regional LNE, when both conducted to an appropriate extent,
was associatedwith the best long-termOS for ES NSCLC. Thismakes it the preferred treatment for ES
NSCLC. However, theremay be situations inwhich SBRT could be a reasonable alternative treatment.
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